VANCOUVER, British Columbia--(BUSINESS WIRE)-- Alpha Cognition Inc. (Nasdaq: ACOG) (“Alpha Cognition”, “ACI”, or the “Company”), a biopharmaceutical company developing and commercializing novel therapeutics for debilitating neurodegenerative disorders, today announced that the United States Patent and Trademark Office (USPTO) published U.S. Patent No. 20260325541-A1, titled “Benzgalantamine for Treating Persistent Post-Concussion Symptoms.”

The published application includes pending claims directed to methods of treating persistent post-concussion symptoms with benzgalantamine. The application describes the use of benzgalantamine in patients experiencing persistent symptoms following mild traumatic brain injury, including cognitive impairment, and includes multiple routes of administration.

Alpha Cognition Announces Publication of U.S. Patent Application for Benzgalantamine for Treating Persistent Post-Concussion Symptoms

Business Wire